secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001104659-22-026319
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco FY21 rev $4,765M, adj EPS $1.05; Q4 adj EPS $0.21 (+75%); FY22 adj EPS guidance $1.18-1.24
--------------------------------------------------------------------------------

- Full year 2021 revenue $4,765M (+46% YoY); reported EPS -$0.97, adjusted EPS $1.05.
- Q4 2021 revenue $1,113M (-2% YoY); adjusted EPS $0.21 (+75% YoY).
- FY22 guidance: revenue $4,745-$4,800M, adjusted EPS $1.18-$1.24.
- Restructuring: ~380 positions cut; synergy target raised to $345M by 2023.
- Board eliminated supermajority voting and adopted proxy access for 3%+ shareholders owning ≥3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000110465922026319/0001104659-22-026319-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000110465922026319/tm227491d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-026319

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer